GlassScriptPhysician profile
Jerry Mcknight
NPI 1356311005
$1,870.32
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $236 · 2021: $80.80 · 2022: $751 · 2023: $541 · 2024: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $802.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $230.92 | 2022-2023 | |
| Novo Nordisk INC | $210.99 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Boston Scientific Corporation | $153.13 | 2022-2024 | Wavewriter Alpha Prime 16 |
| Scilex Pharmaceuticals INC. | $126.46 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.51 | 2021-2023 | Tradjenta, Synjardy, Jardiance |
| Abbvie INC. | $96.61 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $86.22 | 2021-2023 | Farxiga |
| Collegium Pharmaceutical, INC. | $84.13 | 2020-2024 | Xtampza |
| Janssen Pharmaceuticals, INC | $70.46 | 2022-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $66.41 | 2022-2023 | Eliquis |
| Lilly USA, LLC | $57.23 | 2022-2023 | Jardiance |
| Dexcom, INC. | $53.42 | 2023-2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $52.54 | 2022-2023 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.03 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $35.14 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $33.49 | 2020-2024 | |
| Sunovion Pharmaceuticals INC. | $33.06 | 2022 | |
| Astellas Pharma US INC | $29.07 | 2023 | Myrbetriq |
| Amgen INC. | $27.22 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $27.05 | 2024 | Ultomiris |
| Vertos Medical, INC. | $26.13 | 2020 | |
| Endogastric Solutions, INC | $24.83 | 2022 | |
| Forte Bio-Pharma LLC | $24.32 | 2020 | |
| Biodelivery Sciences International, INC. | $22.71 | 2020-2021 | |
| Mylan Specialty L.P. | $21.38 | 2023 | Yupelri |
| Exact Sciences Corporation | $19.90 | 2023 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $17.69 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.71 | 2022 | |
| Merck Sharp & Dohme LLC | $14.42 | 2022 | |
| Currax Pharmaceuticals LLC | $14.39 | 2022 | |
| Philips North America LLC | $12.91 | 2023 | |
| Arbor Pharmaceuticals, INC. | $12.91 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.07 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Mcknight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.